Clinical Trial of Docosahexaenoic Acid in Patients With Retinitis PigmentosaReceiving Vitamin A Treatment

Abstract
Retinitis pigmentosa has a worldwide prevalence of about 1 in 4000 persons.1-10 Affectedpatients typically show elevated dark-adaptation thresholds,11,12 constrictedvisual fields, retinal arteriolar attenuation, intraretinal pigment aroundthe midperiphery, and reduced and delayed electroretinograms (ERGs).13,14 Histological studies have shown thatvisual loss occurs owing to degeneration of rod and cone photoreceptors.15,16 A prior randomized, controlled trialshowed that patients treated with vitamin A palmitate, 15 000 IU/d, had,on average, a slower rate of decline of retinal function as monitored by theERG compared with those not receiving this dose.17

This publication has 13 references indexed in Scilit: